Free Trial

RAPT Therapeutics Q3 2023 Earnings Report

RAPT Therapeutics logo
$0.84 0.00 (-0.21%)
(As of 03:51 PM ET)

RAPT Therapeutics EPS Results

Actual EPS
-$0.82
Consensus EPS
-$0.75
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

RAPT Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

RAPT Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

RAPT Therapeutics Earnings Headlines

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
RAPT Therapeutics Reprices Underwater Employee Stock Options
RAPT Therapeutics Reports Improved Q3 2024 Results
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
See More RAPT Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RAPT Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RAPT Therapeutics and other key companies, straight to your email.

About RAPT Therapeutics

RAPT Therapeutics (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

View RAPT Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings